Ondansetron Enexi

Ondansetron, the active ingredient in Ondansetron Enexi, is a 5‑HT3 receptor antagonist presented as an intravenous solution for injection use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative settings in adult and pediatric patients.

GNH USA supplies Ondansetron Enexi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control emesis in several clinical situations.

- Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: prevents onset of symptoms during and after treatment. - Postoperative nausea and vomiting: helps control symptoms following surgical procedures.

Common Side Effects: - Headache - Constipation - Diarrhea - Injection site pain

Serious or Rare Side Effects: - QT interval prolongation leading to cardiac arrhythmia - Anaphylactic reactions - Serotonin syndrome

Ondansetron should be used with attention to the following precautions: - Cardiac risk assessment: monitor ECG in patients with known QT prolongation. - Concomitant medication review: avoid or adjust drugs that also prolong QT interval. - Hepatic impairment: consider dose reduction in patients with severe liver dysfunction. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several drug classes.

Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., quinidine, amiodarone). - Certain antiarrhythmics (e.g., sotalol). - Serotonergic drugs (e.g., tramadol) that increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin) may raise plasma levels. - CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Anticholinergic agents may diminish antiemetic effect.